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Computational survey of peptides derived
from disulphide-bonded protein loops that
may serve as mediators of protein-protein
interactions
Fergal J Duffy1,2,3, Marc Devocelle5, David R Croucher4 and Denis C Shields1,2,3*
Abstract
Background: Bioactive cyclic peptides derived from natural sources are well studied, particularly those derived from
non-ribosomal synthetases in fungi or bacteria. Ribosomally synthesised bioactive disulphide-bonded loops represent
a large, naturally enriched library of potential bioactive compounds, worthy of systematic investigation.
Results: We examined the distribution of short cyclic loops on the surface of a large number of proteins, especially
membrane or extracellular proteins. Available three-dimensional structures highlighted a number of
disulphide-bonded loops responsible for the majority of the likely binding interactions in a variety of protein
complexes, due to their location at protein-protein interfaces. We find that disulphide-bonded loops at
protein-protein interfaces may, but do not necessarily, show biological activity independent of their parent protein.
Examining the conservation of short disulphide bonded loops in proteins, we find a small but significant increase in
conservation inside these loops compared to surrounding residues. We identify a subset of these loops that exhibit a
high relative conservation, particularly among peptide hormones.
Conclusions: We conclude that short disulphide-bonded loops are found in a wide variety of biological interactions.
They may retain biological activity outside their parent proteins. Such structurally independent peptides may be
useful as biologically active templates for the development of novel modulators of protein-protein interactions.
Keywords: Cyclic peptide, Protein loop, Protein interface, Bioactive peptide, Ribosomal cyclic peptide
Background
Cyclic peptides are macrocyclic peptides which possess
where linear peptide side chains or termini are covalently
bonded to shape the peptide into a ring. Macrocyclic
compounds such as cyclic peptides have been a renewed
focus of drug discovery in recent years [1], and identi-
fying a biologically pre-designed set of cyclic peptides
in protein sequences would be of great potential inter-
est in pharmaceutical development. Many cyclic peptides
*Correspondence: denis.shields@ucd.ie
1School of Medicine and Medical Science, University College Dublin, Belfield,
Dublin 4, Ireland
2Complex and Adaptive Systems Laboratory, University College Dublin,
Belfield, Dublin 4, Ireland
Full list of author information is available at the end of the article
are disulphide-cyclic, where two cysteine residues form
an S-S bond between two thiol side chain groups to
cyclise the peptide. Many other types of cyclic peptide
are possible, including head-tail cyclised peptides, where
the amino N-terminus and carboxy C-terminus are bound
together with an amide bond to cyclise the peptide back-
bone, and other side-chain crosslinked cyclic peptides,
such as those possessing amide bond between a lysine
side chain and an aspartic acid side chain. Side-chain
crosslinked cyclic peptides include disulphide-cyclic pep-
tides, such as those described in this work; cyclic pep-
tides where the side-chains mimic a peptidic bond, such
as Lysine-Aspartic acid side chain cyclised peptides; as
well as depsipeptides, where the side-chain crosslinking
bond is an ester bond. An example cyclic depsipeptide
© 2014 Duffy et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
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would be a serine-aspartic acid side-chain cyclised pep-
tide. There also exist backbone head-tail cyclic peptides
with additional disulphide bonding such as the cyclotides
[2] and theta-defensins [3], where the disulphide bonding
serves to provide additional conformational constraint to
the already cyclic peptide. Cyclic peptides are interesting
from a drug development point of view, due to their gener-
ally better specificity, proteolytic resistance, and stability
than linear peptides [4]. While the term “cyclic peptide”
can refer to a peptide cyclised by any of the above strate-
gies, the term is often used to refer to head-tail cyclised
peptides. Therefore, this work use the term “small macro-
cyclic peptides” to refer to cyclic peptides in general,
including the disulphide-cyclised peptides described in
this work.
Many examples of bioactive and therapeutic natu-
ral peptides are known, including antibiotics [5], natu-
ral hormone mimics [6] and immunosuppresants [7].
The source of these peptides are mostly non-ribosomal
plant and fungal secondary metabolites, produced by
specialised non-ribosomal peptide-synthetase enzymes.
These can create peptides with a wide range of unusual
amino acids, that can be of varying chirality, carry mod-
ified side chains and backbones, and be cyclised [8].
Reviews by Conlon et al. [9] and Cascales et al. [10]
provide more detailed overview of the diversity of small
macrocyclic peptides in nature. The Cybase [11,12]
database has been developed as a publically available
resource describing of sequence, structural and func-
tional properties of naturally derived cyclic proteins and
peptides.
The biological activity of naturally occurring ribosoma-
lly synthesised peptides have not been subject to any sys-
tematic surveys. Disulphide bonds are known to play a key
structural role in proteins, stabilising the protein tertiary
structure on a large scale, and can also influence quater-
nary structure via interchain disulphide bonds. However,
disulphide bonds can also have a local effect in constrain-
ing a much smaller component of the structure. A protein
loop is a general term for a protein secondary struc-
tural element which is not a helix or sheet, and generally
exhibit a lack of hydrogen bonding and high flexibility,
and often served to join other secondary structural ele-
ments. Protein turns are specific types of loops where the
polypeptide chain reverses its overall direction and can be
between 1 and 5 residues long (α, β , γ , δ and π turns) [13].
A special case of this is the β-hairpin turn, which con-
nects two antiparallel β-sheets. These regions are known
to be important in protein-protein contacts [14], and short
(2-8 amino-acid) protein loops or turns can be “pinned”
in place by a disulphide bond [15], forming a surface
structural motif held in a relatively fixed position by the
disulphide bond, thus having a certain amount of inde-
pendence from the larger protein tertiary structure. This
approach has previously been explored in phage-display
studies [16].
The idea of finding “self-inhibitory” peptides, where a
peptide derived from a protein-protein interface inhibits
the formation of that interface, has been previously
explored, and it has been found that many of globular
protein interactions are dominated by linear peptide seg-
ments [17]. Among other applications, this approach
has recently been used to identify peptides that inhibit
viral membrane fusion [18]. Therefore, in principle short
disulphide-bonded loops derived from protein sequences
and located at protein interfaces could be synthesised sep-
arately and show a similar or related biological activity to
the parent protein.
The use of small macrocyclic peptides to mimic protein
loops has also been exploited for the RGD peptides [19].
The RGD tripeptide motif is a cell attachment β-turn
motif found in numerous proteins, and small macrocyclic
peptides containing this motif have been shown to inhibit
integrin αVβ3 activity, which plays an important role in
tumour metastasis.
Traditionally, protein-protein interaction inhibitors are
discovered by screening compounds against a particu-
lar known “target” interaction of interest in a biochem-
ical pathway. Our motivation in this study is to harness
the vast amount of protein sequence and structural data
available to develop a bioinformatic approach to identify-
ing candidate bioactive small macrocyclic peptides from
disulphide-bonded protein loops. In contrast to screening
compounds against a single target, this method of analysis
allows simultaneous identification of modulators against
a variety of protein-protein interactions that have been
evolutionarily selected for. This type of bioinformatics
approach has been previously successfully used to identify
peptides from signalling rich juxtamembrane regions that
have the ability to modulate platelet function [20]. In this
study, we surveyed the sequence, structural and conser-
vation properties of disulphide bonded protein loops, in
order to infer a set of small macrocyclic peptides capable
of bioactivity outside the context of their parent protein.
Results and discussion
Finding disulphide-bonded loops at protein-protein
interfaces
To identify short disulphide bonded loops that play a cru-
cial role at Protein-Protein Interfaces, we set out to find
known three-dimensional structures of protein complexes
mediated by a disulphide bonded loops. We defined short
disulphide bonded loops as those equal to or less than
eleven residues in length (two flanking cysteines, plus
2-9 internal residues), and excluding cysteine-knot like
regions of overlapping disulphide bridges.
2,380 Protein Data Bank (PDB) structures [21] cor-
responding to Uniprot entries with annotated short
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disulphide-bonded loops were downloaded. (Figure 1(a))
Disulphide-bonded loops at protein surfaces or inter-
faces were identified as described in the Methods. The
number of surface residues (defined as those having at
least 2.5Å2 of solvent exposed surface area), and inter-
face residues (those within 3Å of another protein chain)
were counted using PyMol [22]. After removing redun-
dant PDB structures, we found 1,231 short disulphide-
bonded loops at protein surfaces (Figure 1(b)), and 132
short disulphide-bonded loops located at known protein-
protein interfaces (Figure 1(c)). Of these 132 disulphide-
bonded loops, 13 occupied over 50% of the interface
surface area. We also found that the number of protein-
protein interface hotspots contained in these disulphide-
bonded loops, as predicted by the HotRegion [23] server,
is generally proportional to the interface area covered by
the loops (Additional file 1: Figure S1). Thus, the majority
of disulphide-bonded loops at protein-protein interfaces
do not constitute the major determinant of the interac-
tion. Nevertheless, they may still play key roles in binding
and represent potential templates for mimetics that target
protein-protein interactions.
The proteins containing short disulphide-bonded loops
shown in Table 1, are generally membrane, secreted,
or extracellular, with exceptions being palmitoyl-protein
thioesterase 1, in the lysosome. The reason for this is likely
that the disulphide bonds would not last in the reducing
environment of the cytosol. Disulphide bonds can exist
in the cytosol, but they are generally either embedded in
the hydrophobic core of the protein, protected from the
cytosol, or in the presence of sulfhydryl oxidases [24].
Table 1 identifies the 13 proteins containing a short
disulphide-bonded loop comprising over 50% of the sur-
face area of a PDB protein-protein interface, along with
the partner protein at the interface. These interfaces come
from a variety of species, including bacteria (Alcaligenes
sp., E. coli), plants (P. angularis, V. radiata, V. unguicu-
lata), and animals (H. sapiens, M. musculus, N. atra, B.
irregularis). They also cover a variety of protein types,
including snake venoms, proteinase inhibitors, collagen,
and extracellular proteins involved in growth and cell
adhesion.
Structural independence of short disulphide loops
In order to explore the structural independence of short
disulphide bonded loops when removed from their parent
protein, structural models of the short disulphide loops
described in Table 2 were generated using the PEP-FOLD
Figure 1 Loop, surface and interface size distributions for disulphide-bonded loop containing proteins. This study examined a total of 2,380
3D loop structures from 759 unique proteins in the Protein Data Bank (PDB), along with 8,607 annotated disulphide-bonded loop sequences from
5,989 Uniprot protein entries. (a) Shows the loop size distribution of disulphide bonded loops in PDB structures. (b) Shows the distribution of the
number of surface residues possessed by each PDB-derived disulphide-bonded loop (c) shows the distribution of the number of residues in each
PDB-derived disulphide loop that are involved in a protein-protein contact. (d) Shows the size distribution of short disulphide-bonded loops
annotated in Uniprot.
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Table 1 Uniprot Proteins containing a disulphide-bonded
loop comprising over 50% of a PDB protein-protein
interface
Uniprot Protein containing Interacting PDB ID
accession disulphide-bonded loop protein
P02462 Collagen alpha-1(IV) chain
[Cleaved into: Arresten],
Homo sapiens
Homodimer 1LI1
Q7T1K6 Natrin-1 (Cysteine-rich
venom protein 1)
(NA-CRVP1) (Protein G2a),
Naja atra
Homodimer 1XTA
P01133 Pro-epidermal growth
factor (EGF) [Cleaved into:
Epidermal growth factor
(Urogastrone)] , Homo
sapiens
EGF Receptor (ErbB1),
Homo sapiens
1IVO
P01058 Bowman-Birk type
proteinase inhibitor,
Phaseolus angularis
Bovine trypsin 1TAB
P01062 Bowman-Birk type trypsin
inhibitor, Vigna radiata
Trypsin, Bos taurus 1G9I
P17734 Bowman-Birk type seed
trypsin and chymotrypsin
inhibitor (BTCI), Vigna
unguiculata
Trypsin, Bos taurus 2G81
P0AD59 Inhibitor of vertebrate
lysozyme, Escherichia coli
Lysosome C, Gallus
gallus
1GPQ
Q9JHF9 Lymphocyte antigen 96
(Ly-96) (ESOP-1) (Protein
MD-2),Musmusculus
Toll-like receptor 4
(TLR-4),Musmusculus
2Z64
A0S865 Irditoxin subunit B (IrTxB),
Boiga irregularis
Iridotoxin subunit A 2H7Z
P50897 Palmitoyl-protein
thioesterase 1 (PPT-1) (EC
3.1.2.22) (Palmitoyl-protein
hydrolase 1), Homo sapiens
Homodimer 3GRO
P04004 Somatomedin-B subunit
of Vitronectin (VN), Homo
sapiens
Plasminogen activator
inhibitor-1 (PAI-1),
Homo sapiens
1OC0
P04004 Somatomedin-B subunit
of Vitronectin (VN), Homo
sapiens
Urokinase plasminogen
activator surface
receptor (uPAR), Homo
sapiens
3BT2
Q03405 Urokinase plasminogen
activator surface receptor
(uPAR), Homo sapiens
Urokinase-type
plasminogen activator
(uPA), Homo sapiens
3BT2
Q8RS40 Beta-1,3-xylanase (txyA),
Alcaligenes sp.
Homodimer 2COV
[25] de-novo peptide structure prediction webserver.
These models were generated from the sequence of
the disulphide loop alone. Five PEP-FOLD model struc-
tures were generated for each disulphide bonded loop in
Table 2. The PyMol [22] align tool was then used to align
each model disulphide loop to the PDB crystal structure
based on backbone Cα atoms, and calculate an RMSD
between the crystal structure and model. The complete
results are shown in Additional file 1: Table S1.
Table 2 Protein families containing preferentially
conserved disulphide-bonded loop
Protein family Disulphide-bonded
loop count
Somatotropin 91
Prolactin 50
Polygalacturonase/Endopolygalacturonase 50
Guanylate cyclase activator/Guanylin 13
Urotensin 12
Disintegrin 8
Calcitonin 6
Other 57
Total 287
(Conservation difference between disulphide-bonded loop and juxtapeptide
region of over 0.30.).
The mean RMSD of the lowest energy PEP-FOLD
model to each corresponding crystal structure was
2.468 ± 0.767Å. As a point of reference, the ongoing
Critical Assessment of Techniques of Protein Structure
Prediction (CASP) experiment describes the generation
of a homology structure with an accuracy of better than
6.5Å as “not trivial”, and models with an accuracy of
1.5Å as “high-resolution”. Models with an RMSD of 4Å
can be considered as having a broadly correct fold [26].
Using these values as a guideline it seems that disulphide-
bonded loop structure prediction using the loop sequence
alone is sufficient to predict a moderately accurate struc-
ture, lending support to the idea that these loops have a
large degree of structural independence from their parent
protein.
Short disulphide-bonded loopmediated interfaces
For many of the heterodimeric interfaces listed in Table 1,
there is additional experimental evidence to suggest that
the short disulphide-bonded loops play a key role in bind-
ing. In the case of the interaction of Egg Lysosyme and
Inhibitor of Vertebrate Lysosyme (Ivy), a cyclic loop on the
surface of Ivy (CKPHDC) has been shown to be essential
for its inhibitory effect, as shown by mutagenesis stud-
ies [27]. This loop is strictly conserved across 30 members
of the Ivy family, and 5 other members contain a related
CExxDxC motif.
For the Lymphocyte antigen 96 and Toll-like receptor 4
interaction, a disulphide-bonded loop CHGHDDDYSFC
sits on the conserved “A” patch of Lymphocyte antigen 96.
Mutations of five separate amino acids in this peptide have
been shown to disrupt binding, including both cysteine
residues, implying that the cyclic nature of the peptide is
important for complex formation [28].
A CSYYQSC disulphide-bonded loop contained within
Vitronectin is located at the interface of two protein-
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protein complexes, those of Vitronectin with Plasmino-
gen activator inhibitor-1 and Vitronectin with Uroki-
nase plasminogen activator receptor. The relevance of
the short disulphide-bonded loop to the interaction of
Vitronectin and Plasminogen activator inhibitor-1 has
been experimentally verified. Alanine scanning shows that
deletion of Asp22, Glu23, Leu24, Tyr27 and Tyr28 sig-
nificantly reduces binding affinity. The cyclic region of
the interface covers the Cys25 to Cys31 region, includ-
ing 2 of the 5 critical residues [29]. The same Vitronectin
disulphide-bonded loop is critical in the binding of Vit-
ronectin to urokinase plasminogen activator receptor. The
four serine (Ser26, Ser30) and tyrosine (Tyr27, Tyr28)
residues in the disulphide-bonded loop fit into a cav-
ity on Urokinase plasminogen activator receptor that
shows a high degree of shape and charge complementar-
ity [30]. Notably, the same disulphide-bonded loop tyro-
sine residues are important in Vitronectin binding to both
Urokinase plasminogen activator receptor and Plasmino-
gen activator inhibitor-1. Also, a Urokinase plasminogen
activator receptor disulphide-bonded loop, CKTNGDC,
is involved in the interaction of Urokinase plasminogen
activator receptor with Urokinase plasminogen activa-
tor, in direct contact with the Urokinase plasminogen
activator Kringle domain. However, this Urokinase plas-
minogen activator receptor disulphide-bonded loop is not
located close to the Vitronectin binding region [30]. The
three proteins Urokinase plasminogen activator recep-
tor, Urokinase plasminogen activator and Vitronectin play
important roles in regulating the proteolytic degrada-
tion of the extracellular matrix and blood clots [31].
This network can also play a role in cancer progression,
including degrading the extracellular matrix to facilitate
cancer metastasis [32]. Thus a small macrocyclic peptide
that can interfere with this network would be of clinical
interest.
The Epidermal growth factor disulphide-bonded loop
CVVGYIGERC interacts with domain I and III of the Epi-
dermal growth factor receptor [33]. The position of the
disulphide-bonded loop region at the interface is evident
in Additional file 1: Figure S2, but there is no evidence
whether this disulphide-bonded loop may have indepen-
dent activity. The Epidermal growth factor receptor is part
of the ErbB family of receptor tyrosine kinases which act
as receptors for a variety of different Epidermal growth
factor-domain containing growth factor ligands. All of
these Epidermal growth factor domains contain homolo-
gous C-terminal disulphide-bonded loops.
Along with their role at the binding interfaces between
different proteins, it can be seen from Table 1 that
disulphide-bonded loops are also involved in interac-
tions between protein subunits (Natrin-1, Iridotoxin),
and between homodimeric interfaces (Collagen α-1(IV)
homodimer, Palmitoyl-protein thioesterase homodimer).
For the cases discussed above (Inhibitor of Vertebrate
Lysosyme, Lymphocyte antigen 96, Vitronectin, Epider-
mal growth factor), the disulphide-bonded loop con-
tains all or part of the protein region responsible for
the interaction, and it would be interesting to deter-
mine if the disulphide-bonded loop portion of the inter-
face alone is sufficient to modulate the protein-protein
interaction.
A disulphide-bonded loop region in Bowman Birk inhibitors
possesses independent activity
For one of the interfaces in Table 1 it has been previously
shown that the short disulphide-bonded loop portion of
the interface is not only a critical part of the interaction,
but can act independently of the parent protein. This is
the Bowman-Birk family of serine proteinase inhibitors,
where the a single disulphide-bonded loop in the protein
can act as an inhibitor of trypsin at nanomolar concen-
trations. The active disulphide loop of the Bowman-Birk
inhibitor is nine residues, and Luckett et al. [34] have iden-
tified a natural sunflower cyclic Bowman-Birk inhibitor 14
residues long (SFTI-1).
The inhibitory abilities of the disulphide-bonded loop
alone has been demonstrated by Domingo et al. [35], who
designed a set of eleven residue small macrocyclic peptide
loops based on this loop from a variety of Bowman-Birk
serine protease inhibitors, and showed that the resulting
small macrocyclic peptides inhibit a similar set of serine
proteases as the parent protein. The native Bowman-
Birk proteins inhibit at picomolar concentrations, and the
disulphide-bonded loops at nanomolar concentrations -
which is the range that would be expected from a druglike
molecule. This result is promising from the point of view
of using these loops as lead peptides for drug discovery
efforts.
EGF domain small macrocyclic peptides do not show
independent activity
To investigate if human disulphide-bonded loops at PDB
interfaces can have biological activity when extracted
from their parent protein, we tested whether the EGF
disulphide-bonded loop identified in Table 1 along with
a panel of 14 homologous disulphide-bonded loops from
related EGF-domains (Table 3) could modulate EGF
receptor behaviour. These sequences were chosen to rep-
resent well-described ErbB agonists [36]: a closely related
set of growth factors along with a sampling of other
diverse EGF domains. The disulphide-bonded loops listed
in Table 3 are mostly derived from a closely related set
of growth factors in the ErbB pathway, along with a sam-
pling of other diverse EGF domains. Thus, from a single
candidate disulphide-bonded loop, a library of related
disulphide-bonded loops generated during evolution can
be assessed for potential biologic activity.
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Table 3 Cyclic peptides derived from EGF-domain
containing proteins and tested for EGF
activation/inhibition
No. Cyclic peptide sequence Human parent protein
1 CVVGYIGERC EGF, Epidermal Growth Factor*
2 CHSGYVGARC TGFA, Transforming Growth
Factor Alpha*
3 CQQEYFGERC AREG, Amphiregulin*
4 CDEGYIGARC BTC, Betacellulin*
5 CHPGYHGERC HBEGF, Heparin-binding EGF-like
growth factor*
6 CEVGYTGVRC EREG, Epiregulin*
7 CQPGFTGARC NRG1, Neuregulin-1**
8 CPNGFFGQRC NRG2, Neuregulin-2**
9 CKEGYQGVRC NRG3, Neuregulin-3**
10 CVENYTGARC NRG4, Neuregulin-4**
11 CAQECVHGRC PEAR1, Platelet endothelial
aggregation receptor 1
12 CTRTGYSGPNC PTGS1, Prostaglandin G/H
synthase 1
13 CDPGFSGLKC SELE, E-selectin
14 CLPAFEGRNC F7, Coagulation factor VII
15 CDSDWTGYYC ITGB3, Integrin Beta 3
*Denotes growth factors known to directly activate the EGF receptor. **Denotes
growth factors known to directly activate members of the ErbB receptor family
other than EGFR/ErbB1.
These loop-derived small macrocyclic peptides were
synthesised separately and tested for their ability to 1)
activate the EGF receptor and 2) competitively inhibit
the EGF receptor in the presence of native EGF. Western
blotting was used to assess the amount of phosphory-
lated EGFR after treatment with EGF, small macrocyclic
peptide, or EGF following incubation with small macro-
cyclic peptide, as a proxy for activation. However none of
the selected peptides demonstrated any ability to either
activate or inhibit the EGF receptor (Additional file 1:
Figure S3). We conclude that these peptides do not show
significant biological activity independent of their par-
ent protein, in contrast with the Bowman-Birk protease
inhibitor peptides.
It is possible that the disulphide loop takes a signifi-
cantly different shape when removed from the context of
the wider EGF protein, hence explaining the lack of bio-
logical activity observed. Additional file 1: Table S1 shows
that the lowest energy de-novo model of this loop has an
RMSD of 2.374Å based on the Cα alignment. This sug-
gests that the free peptide retains a structure reasonably
close to what has been seen in the crystal structure.
To explain why these EGF peptides do not have activ-
ity, we examined the structure of the EGF-EGFR complex.
(PDB ID: 1IVO). The EGFR protein comprises three struc-
tural domains (I, II, and III). EGF activates EGFR by
binding to a cavity between EGFR domain I and III, with
binding sites existing on both domain I and III [33]. The
CVVGYIGERC loop (Cys33 - Cys41 of EGF) tested here
comprises a large portion of the total EGF-Domain I inter-
face contacts in the crystal structure, but only a small
proportion of the EGF-Domain III contacts (Additional
file 1: Figure S2). Residues in the C-terminal end of EGF,
such as Leu47 are known tomake important contacts with
Domain III. Thus, despite comprising a large portion of
the interface, the disulphide loop is not able to fill the
EGFR cavity on both sides, which would likely explain why
the disulphide bonded loop is not able to conformation-
ally shift EGFR to its active position. It is possible that the
disulphide bonded loop is binding to Domain I of EGFR,
but clearly any potential binding is not strong enough to
compete with EGF binding to its native receptor.
Conservation of disulphide-bonded loops
The cyclic-peptide mediated interfaces above represent
an interesting set of compounds, but it is also of inter-
est to see if disulphide-bonded loops represent a widely
used natural strategy to influence protein-protein inter-
actions, by examining evolutionary conservation of short
disulphide-bonded loops in proteins.
A dataset of short disulphide-bonded loop contain-
ing proteins was assembled from the SwissProt database
of manually annotated proteins. Searching for all Swis-
sProt proteins containing short disulphide bonded loops
(annotated intrachain disulphide bonds with 2-8 inter-
nal residues) revealed 8607 annotated short disulphide-
bonded loops in 5989 proteins (Figure 1(d) shows the
size distribution of these loops). Figure 2 illustrates the
distribution of amino acids in short disulphide-bonded
loops, as compared to that of the full range of pro-
teins in Uniprot. Short disulphide-bonded loops seem
to contain fewer hydrophobic residues (Valine, Leucine,
Isoleucine, Alanine, Methionine) which could indicate
that disulphide-bonded loop loops are relatively unlikely
to be located at the hydrophobic core of a protein. There is
also an enrichment in Glycine and Proline residues, which
are known to enable protein backbone flexibility [37], and
break up helical structures [38], which may enable turns,
helping the cycle to be formed.
Homologs of SwissProt proteins containing annotated
short disulphide-bonded loops were identified using the
Gopher [39] webserver (bioware.ucd.ie), searching the
default set of model organisms. All short disulphide-
bonded loop containing proteins with at least one
Gopher-identified ortholog were then aligned using
MUSCLE [40]. Per-residue conservation scores were then
calculated for each alignment using the Jensen-Shannon
divergence method of Capra and Singh [41]. Aligned
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short disulphide regions between the original protein and
homolog were identified by examining alignments of the
annotated disulphide regions of the original protein. If
the loop terminal cysteine residues in the original protein
exactly aligned with cysteine residues in the homolog pro-
tein, this region was considered a conserved disulphide
loop. It is well known that cysteines involved in disulphide
bonding are well conserved across a variety of protein
families [42]. For this reason, only the conservation of the
interior loop residues was considered in this study.
Short disulphide-bonded loops show increased conser-
vation relative to other regions in the same set of pro-
teins(Figure 3). It is possible that the higher conservation
of these loops come from loop sequences being dom-
inated by turn-promoting residues such as proline and
glycine, which are somewhat over-represented in disul-
phide bonded loops, as shown in Figure 2. However it
has also been observed that residues with high solvent
accessibility are more variable between homologs [43,44]
than internal residues. Since we have observed that known
3D disulphide bonded loop residues are mostly exposed
on the protein surface (Figure 1(b)), this variability will
tend to counteract the increased likelihood of proline and
glycine residues in the loop aligning by chance.
Disulphide-bonded loops demonstrate a strongly sta-
tistically significant increase in conservation relative
to residues immediately adjacent to the cyclic region
(Figure 4), however, this increase is very modest in scale,
suggesting that disulphide-bonded loop regions may often
be embedded within regions of more extended structural
constraint. We noted that in our dataset, the increased
conservation within disulphide-bonded loops relative to
adjacent regions was limited to residues 1,3 and 4 places
from the cyclic cysteines and was not seen at the posi-
tion two residues away. It is not clear why this would be
the case, but it is possible that residues with reducing
effects may have more influence at certain distances and
avoidance of these effects may impact on the pattern of
conservation.
It may well be that disulphide-bonded loops with stand-
alone function are more likely to be conserved relative
to their immediately adjacent residues. Figure 5 shows
the distribution of differences in conservation between
disulphide-bonded loops and their immediate surround-
ing residues.
The surface and interface disulphide-bonded loops
show a similar distribution to other cyclic regions. Thus,
simply existing at a protein surface or interface does not
Duffy et al. BMC Bioinformatics 2014, 15:305 Page 8 of 14
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mean that a disulphide-bonded loop will be preferentially
conserved.
However, the graph does have a smaller second peak at
about 0.30, indicating a set of disulphide-bonded loops
that are significantly more conserved than their adjacent
residues. Table 2 lists the names of the protein families
that contain these highly conserved disulphide-bonded
loops. Over half are secreted short proteins and peptide
hormones such as somatotropin, prolactin, guanylin and
urotensin, as well as the larger polygalacturonase from
plants. Many of these peptides and proteins are very short,
such as guanylin (15 amino acids) and urotensin (11 amino
acids), with the disulphide bonded section making up
over half of the peptide length. Given the lower conser-
vation outside the cyclic region, such proteins are good
candidates for investigating the role of the cyclic regions
alone.
Viral proteins as sources of bioactive disulphide-bonded
loops
It is known that viruses can rapidly co-evolve many of
the same protein-protein regulatory strategies as their
hosts [45]. We scanned viral proteins for disulphide-
bonded loops that may mimic host disulphide-bonded
loops mediating interactions. Table 4 shows virus pro-
teins containing disulphide-bonded loops, similar to a
human disulphide-bonded loop, where there is at least one
human-virus protein interaction described in an interac-
tion database.
The match of an adenoviral peptide CNSSTDSC to a
human integrin β-6 CTTSTDSC disulphide-bonded loop
was of most interest, since viral proteins exploit extra-
cellular matrix and integrin interactions to facilitate cell
adhesion and entry. The integrin CTTSTDSC loop is
located in the third EGF-like repeat domain region of the
extracellular portion of Integrin β-6. This region is known
to be “masked” in the integrin’s inactive conformation,
and exposed in the active conformation [46]. The human
herpesvirus ssDNA binding protein binds the secreted
FBLN5 protein: (Additional file 1: Table S2) the viral
peptide CRRPC resembles the human ERBB2 CSKPC
peptide somewhat. This similarity is relatively weak, but
it is intriguing that the FBLN5 protein contains 9 EGF
domains, since ERBB2 belongs to a receptor family known
to bind EGF domains.
Many of the matches described in Table 4 consist of
quite short disulphide loops, 5 or 6 residues long, which
points to the possibility of these matches being a chance
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occurrence. However, as described above, there is some
biological support for considering viral proteomes as rep-
resenting potential sources of cyclic bioactive peptides
worthy of further investigation.
Perspectives on disulphide-bonded loops in
protein-protein interactions
We would have expected to uncover more disulphide-
bonded loops that play key roles in protein-protein inter-
actions, given the importance of cyclic compounds in
modulating both enzyme and protein-interactions. It is
possible that the selection of small loops within larger pro-
teins is, in general, slower to evolve to the required degree
of specificity of interaction than the evolution of larger
complementarities between interacting proteins. Thus, in
general, proteins do not often seem to evolve structured
loops as independent determinants of protein interac-
tion. This is in contrast to eukaryotic Short Linear Motifs
(SLiMs) [47] which have specifically evolved to match
particular motif binding domains. Why it is that biology
has decided to focus on linear motifs rather than cyclic
motifs in eukaryotes is not clear. However, it is worth
noting that many linear motifs, although they bind inde-
pendently, typically bind with modest affinity, in a manner
that suggests that modest affinity is optimal [48]. Thus,
the benefit of higher affinity binding that cyclic loops
might confer may not be advantageous in the context of
SLiM signalling, perhaps explaining why our survey has
revealed relatively few such interactors. While there are
examples of such loops having independent effects from
the literature, overall, it may be that mining existing cyclic
loop sequences from protein interactions may not be a
very fruitful strategy for discovering novel modulators of
protein-protein interactions, although we must point out
that our own experimental validation only considered one
class of such loops.
Conclusions
Considering a small disulphide-bonded loop as a surface-
exposed loop pinned in place by a pair of cysteines, the
structure of this loop could be relatively independent of
the sequence of the larger protein, and mostly deter-
mined by the amino acids between the cysteines, due to
the conformational constraint imposed by the disulphide
bond, and the solvent exposed nature of a surface loop.
Thus, a disulphide-bonded loop known to be at a protein-
protein interface could on its own, potentially maintain
the same binding activity as the parent protein. Since
cyclic peptides are known to be more “drug-like” than lin-
ear peptides, this approach could provide a promising set
Duffy et al. BMC Bioinformatics 2014, 15:305 Page 10 of 14
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of biologically-optimised lead-like molecules to attack the
difficult problem of modulating protein-protein interac-
tions [49]. We have contrasted two cases in this study, that
of the Bowman-Birk protease derived small macrocyclic
peptides, which are known to have independent biological
activity, and compared this with a range of EGF-derived
small macrocyclic peptides, which do not, showing that
while ribosomally derived disulphide-bonded loops can
be a promising source of bioactive macrocycles, they may
not contain the necessary binding features, even when
they make up a majority of a protein-protein interface.
Bowman-Birk inhibitors are currently being investigated
for their applications in fighting colorectal cancer, due to
promising mouse results [50].
A disadvantage of re-purposing disulphide bonded
loops as small macrocyclic peptides is that disulphide
bonds are more easily broken than the amide bonds
present in a traditional head-tail cyclic peptides. Nyugen
et al. [51] have compared the serum stability of short (6
residue) antimicrobial linear peptides to the disulphide
and head-tail bonded equivalents, and observed that while
linear peptides will be 80% degraded in serum over the
course of an hour, disulphide-bonded peptides retain over
50% of their original concentration after 2 hours, and
head-tail bonded peptides retain over 70% of their orig-
inal concentration after 6.5 hours. The concentration of
the short depsipeptide arenastatin A in mouse serum has
been observed to decline 50% in an hour [52], leading to
the conclusion that head-tail bonding is themost desirable
from a serum stability point of view. There are a number
of well-described strategies which can be used to improve
the stability and bioavailability of peptide drugs in the
bloodstream [53], and these strategies, along with substi-
tuting disulphide bonds for another cyclisation method
may be necessary to develop a truly “drug-like” molecule.
Despite being mainly restricted to extracellular or vesic-
ular compartments, short disulphide-bonded loops are
relatively widespread with 720 out of a total of 20,252
human proteins in the SwissProt database of manually
curated proteins contain annotated disulphide-bonded
loops. Disulphide-bonded loop residues are more con-
served than non-cyclic residues in the same set of pro-
teins, and are also more conserved than residues located
directly beside short disulphide-bonded loops. While the
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Table 4 Similar disulphide-bonded loops between human and virus
Human Human Human Virus Virus Virus
accession peptide protein name accessions peptide protein name
O43506 CELQWC ADAM20: Disintegrin
and metalloproteinase
domain-containing
protein 20
Q1HVB5 CELGWC Uncharacterized protein
BNLF2b: Human
herpesvirus 4
P22413, Q13822 CKGRC ENPP1 and ENPP2:
Ectonucleotide pyrophos-
phatase/phosphodiesterase
family member 1 and 2
O41974 CKRRC Immediate-early protein,
73: Murid herpesvirus 4
P04626 CSKPC ERBB2: Receptor tyrosine-
protein kinase erbB-2
P03227 CRRPC Single stranded DNA-
binding protein: Human
herpesvirus 4
P00451 CRAPC F8: Coagulation factor VIII P03227 CRRPC Single stranded DNA-
binding protein: Human
herpesvirus 4
P18564 CTTSTDSC ITGB6: Integrin beta-6 P03254 CNSSTDSC Early E1A 32 kDa protein:
Human adenovirus 2
Q96LB9 CTVSTDC PGLYRP3: Peptidoglycan
recognition protein 3
Q77PU6 CTIRSDC Protein U90: Human
herpesvirus 6B
Q92954, P04004 CKGRC PRG4: Proteoglycan 4 and
VN: Vitronectin
O41974 CKRRC Immediate-early protein,
73: Murid herpesvirus 4
conservation is modest, there is a subset of peptides which
show marked conservation (see Table 2), mainly short
secreted peptide hormones or chemical messengers.
This is possibly due to cyclisation by disulphide bond-
ing being the simplest way to impose some structure
on a short peptide, which may not have the size to
form hydrogen-bonded secondary structural features like
helices or beta-sheets. Potential disulphide-bonded loops
are also seen in viral proteins, and a subset of these may
play potential roles in viral adhesion and entry, or other
aspects of viral biology.
This study has used the approach of mining sequence
databases for putative disulphide bonded disulphide-
bonded loops, conserved relative to their adjacent
residues, thus generating a library of compounds of inter-
est. Table 1 contains 13 disulphide bonded loops from
well characterised interaction crystal structures, of which
only the Bowman-Birk type loops have ever been tested
for their independent activity prior to this study. The
disulphide bonded loops of interest include not only the
loops described in Table 1, but, as the PDB currently
only contains structures for a tiny fraction of all possible
protein-protein interactions, the 1,231 short disulphide
bonded loops at protein surfaces (Additional file 1: Table
S3) are also of worthy of investigation, along with the 287
highly conserved disulphide-bonded loops mentioned in
Table 2 which are further described in Additional file 1:
Table S4.
It is well known that small macrocyclic peptides repre-
sent a class of molecules with a wide range of biological
activities, and therefore merely showing that there exist
bioactive small macrocyclic peptides derived from larger
proteins would not represent any furthering of scientific
knowledge. Thus, the key novelty of this work is in explor-
ing how to systematically harness sequence, structural,
and evolutionary data over all well characterised proteins
in order to identify bioactive proteins. This work both
develops a method for identifying potentially bioactive
compounds, as well as providing a list of disulphide-
bonded loop-protein interaction pairs, readily synthesis-
able and open to medium or high throughput functional
screening for binding or activity.
Methods
Assessing short disulphide-bonded loop structures
Protein data bank (PDB) structures containing short
disulphide-bonded loops were identified by searching
UNIPROT for manually curated proteins containing
a non-overlapping disulphide loop with 2-9 internal
residues, with a listed entry in the PDB. The biologi-
cal assembly format (.pdb1) of each PDB structure was
downloaded. Choosing the biological assembly format
ensures that the downloaded structure is the biologi-
cally relevant form of the structure, as opposed to the
crystallographic asymmetric unit, which are not always
the same thing. A PyMol [22] script was used to iter-
ate over each structure file, and test each possible pair of
cysteine residues spaced up to 11 residues apart in the
same protein chain to see if a disulphide bond existed,
by checking whether an S-S bond of approximately 2.05
Å existed. For each short disulphide-bonded loop found,
the number of surface residues were found by considering
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a residue with a solvent accessible surface of over 2.5
Å2. The number of residues at a protein-protein inter-
face was found by counting as an interface residue all
amino acids with heavy atoms within 3Å of another
protein chain.
EGF receptor activation and competition assays
MCF10A immortalised breast epithelial cells were serum
starved for 3 hours before all experiments. For activa-
tion experiments, cells were incubated with either 100μM
small macrocyclic peptide or 10 nM EGF for 5 minutes.
For EGF/small macrocyclic peptide competition assays,
the cells were incubated with 100 μM small macrocyclic
peptide for 5minutes before incubating for another 5min-
utes with 1 nM EGF. EGF Receptor activation was then
measured by western blotting for phosphorylated Tyro-
sine 1173 on EGFR, along with blotting for total EGFR and
total Actin.
Predicting short disulphide-bonded loops in viruses using
protein structural information
Likely short disulphide-bonded loop locations were pre-
dicted based on sequence, secondary structure and sol-
vent accessibility information. Secondary structure and
solvent accessibility were predicted by the Porter and
PaleAle servers from the Distill [54] suite of protein struc-
tural prediction servers. Portions of sequences under 11
residues were included that 1) started and ended with
a cysteine, 2) contained no internal cysteine residues, 3)
were in a region of a protein that was not predicted to
be a β sheet or an α helix, and 4) had an average solvent
accessibility of the region that was predicted to be more
exposed than buried.
Scoring similarity of short disulphide-bonded loops
The similarity of two disulphide-bonded loop sequences
was found by aligning the disulphide-bonded loop
sequences, excluding the flanking cysteine residues, using
the Bio.pairwise2.align function from the BioPython [55]
package, which implements pairwise sequence alignment
using a dynamic programming algorithm, scored with the
BLOSUM62 scoring matrix, and a gap opening and exten-
sion penalty of -12. (This gap penalty is three times the
BLOSUM62 penalty for the most dissimilar amino-acids,
in order to obtain very similar length disulphide-bonded
loops). The maximum possible alignment score was cal-
culated by aligning the viral short disulphide-bonded loop
to itself, and similarity between human and viral peptides
was calculated as
alignmentscore/alignmentscoremax
Identifying viral disulphide-bonded loops similar to human
proteins
Human and virus proteins containing SwissProt anno-
tated short disulphide-bonded loop regions were iden-
tified or predicted using DISTILL as described above.
To identify similar viral proteins, we set out to find
1) disulphide-bonded loops with similar sequences in
human and viral proteins 2) where the viral proteins had
known human interactor proteins 3) where the human
proteins interacting with the viral proteins containing a
short disulphide-bonded loop also interacted with the
original human proteins containing the similar short
disulphide-bonded loop.
Uniprot accession numbers were used to uniquely iden-
tify proteins, and pairs of Uniprot accessions parsed from
the interaction files were used to identify interactions.
Similarity between human and virus short disulphide-
bonded loop sequences was calculated by aligning and
scoring the peptides using the BLOSUM62 substitution
matrix to identify similar short disulphide-bonded loops
in host and virus. Virus and human short disulphide-
bonded loops with a similarity of greater than 0.50 were
identified, and checked for shared interactors.
To find which human and virus proteins shared inter-
actors, the sets of known human protein interactions
(including human-virus interactions) were downloaded as
PSI-MITAB format text files. A text file of human binary
protein interactions was downloaded from theMINT [56]
database (download date: 08/Apr/2013), which was then
parsed to extract human-virus interactions only. A text
file of human-virus protein binary interactions was down-
loaded from the Virhostnet [57] database (download
date: 24/Apr/2013), and text files containing human-virus
binary interaction data for each of the virus species
available in the BioGRID [58] database were also down-
loaded (download date 24/Apr/2012). All three interac-
tion sources were combined into a single dataset and
compared with the list of virus and human proteins
with a similarity greater than 0.50, to identify shared
interactors.
Additional file
Additional file 1: Supplementary material. Contains supplementary
tables and figures referred to in the article.
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